MLNM- ZAHLEN laut CBS-Marketwatch 0,02$ Verlust, ERGEBNIS BESSER - 500 Beiträge pro Seite

[boehseJ]

@all


Geht mal auf die Seite!!!!

Ist ne ReutersMeldung!

Kann Sie vielleicht jemand hier übersetzt reinstellen???

Danke

[rockdj]

Ich glaube, wir können wirklich durchatmen

lt. Reuters Sec. bei yahoo.com

Verluste geringer als erwartet!!!!

[igor1]

!!Millennium Pharmaceuticals Q4 loss lower than expected

NEW YORK, Jan 23 (Reuters) - Biotech firm Millennium Pharmaceuticals Inc. <MLNM.O> on Tuesday reported a lower than expected loss in the fourth quarter, compared with a slight profit in the same period last year.

The Cambridge, Mass.-based company, which uses an array of sophisticated equipment to discover genes and their functions, reported a quarterly net loss, before special items, of $4.4 million, or 2 cents per share, compared to a profit of $1.7 million, or 1 cent per share, in the year ago period.

Analysts polled by research firm First Call/Thomson Financial expected the company to lose 5 cents per share.

Revenues, all from alliances with other firms, rose to $70 million from $55 million in the year-ago period, amid growing numbers of alliances with other biotech firms and interest from investments. But its research and development costs rose to $78 million from $47 million in the 1999 quarter.

((New York Health Desk, 212 859 1870. To access an earnings table for the above company, please look for a separate item headlined "TABLE-" under the company`s ticker symbol. Click on [nN04639427] to see details of new format on S&P 500 earnings coverage.))

REUTERS

Rtr 16:43 01-23-01

[thomy18]

warum wird dann auf ntv so ein blödsinn verzapft?! :-(

[bandolin]

Hi igor,

verrat mir doch bitte, wo ich die geshortete Zahl der Aktien nachlesen kann.

MfG

bandolin

[kaminski]

jetzt verstehe ich,warum der Kurs nachbörslich nicht zusammengebrochen ist.

aufatmen !




KAM

[boehseJ]

Ich kann zwar nicht so gut Englisch, aber ich denke schon das da ein Verlust von -0,02$ steht und auch das Wort besser!!!

Wenn hier jetzt NTV so eine Scheisse erzählt und es hier die dummen Lemminge nachmachen müssen---na ja--ohne Worte....

Auf jeden Fall ist garantiert bei vielen das Herz in die Hosentasche gefallen und mir hat es erst mal den ganzen schönen Abend vermiest!!!

SCHEISS NTV

[thomy18]

mensch hier hat die ganze biotech ecke gezitttert!!!!!

[Pannenoli]

Mir ist am Anfang auch fast das Herz stehengeblieben -
aber es war dann doch wie meistens.
Irgendwas bringen die Jungs immer durcheinander.
Deshalb sitze ich auch jetzt hier um das Ganze zu
checken.

[igor1]

SCHEISS NTV ich habe beim L&s verkauft !!!!!!!!!!!
54,60

@ bandolin
habe im MLNM board gefunden
bei yahoo.com

[fishhawk]

Definitiv die Ergebnisschätzung um 3 Cents getoppt, allerdings sind die Umsätze weit weniger gestiegen als die Forschung und Entwicklungskosten.

Welche Zahlen Jens Korte hatte weiß ich nicht, die 2 Cents beziehen sich auf das Ergebnis ohne Sondereinflüsse.

[dismas]

Informationen aus (zumindest beinahe )erster Hand gibt es auf yahoo.finance. Da kann man den ganzen Bericht nachlesen - natürlich auf Englisch:
http://biz.yahoo.com/prnews/010123/ma_milleni.html.

P.S. thomy18: das meinst du doch nicht ernst?!

[reichinrente]

Jauu, der abend ist gerettet. Mich ärgert nur, dass die bei NTV so einen Scheiß erzählen - das ist jetzt schon öfters vorgekommen!! Sollte man verklagen, wegen Verbreitung von Unwahrheiten. Na egal, Hauptsache unser Bio-Schätzchen enttäuscht uns nicht.
RiR

[proteindesigner]

schön und gut......!!!
aber warum explodiert der kurs nachbörslich nicht?????

p.d.

[Thommyknocker2000]

Hallo!Kann mir mal endlich einer sagen, wie die genauen Zahlen von Millennium sind. DANKE!!!!!!!

[canmed]

laut den amis (nasdaq,yahoo,mlnm)ist das ergebnis= -0,02 $ pro aktie.erwartet wurden -0.05$.das erklärt auch den ruhigen nachbörslichen handel (mlnm=51,75 $).jetzt erst mal darüber schlafen und morgen das plus wieder geniesen.

[Thommyknocker2000]

Danke! Eine gute Nacht! Auf eine schöne Performance!!!!

[harmon]

24.01. 00:07
Millennium: Verlust geringer als erwartet!
--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)

Das Biotechunternehmen Millennium Pharmaceuticals berichtete am Dienstag über einen geringer als erwartet ausgefallenen Verlust im vierten Quartal. Der Verlust wurde mit 4,4 Mio $ oder 2 Cents/Aktie angegeben, gegenüber einem Gewinn von 1,7 Mio $ oder 1 Cent/Aktie ein Jahr zuvor. Analysten hatten aber mit einem Verlust von 5 Cents/Aktie gerechnet.
Die Umsätze stiegen im Jahresvergleich von 55 Mio $ auf 70 Mio $ an. Die angefallenen Verluste sind auf enorm erhöhte Ausgaben für Forschung und Entwicklung zurückzuführen.
Die Aktie notiert aktuell nachbörslich unverändert nachdem sie im freien Handel um knapp 10% gestiegen war.

© BörseGo.de



Harmon

[harmon]

2001 Press Releases


--------------------------------------------------------------------------------

Millennium Reports Year End 2000 Financial Results

Provides 2001 Financial Guidance


CAMBRIDGE, Mass., January 23, 2001 -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported consolidated financial results for the year ended December 31, 2000.

The following financial results exclude the impact of the Company`s adoption of SAB 101, acquisition-related charges, and debt conversion expenses. For a discussion of SAB 101`s impact on the Company`s financial results see section entitled "Effect of SAB 101" below.

Revenue for the year ended December 31, 2000 was $213.2 million compared to $183.7 million in 1999. The increase in revenue is due to the addition of new alliances formed in 2000 and the ongoing success of existing relationships. We believe that our new and existing alliances continue to validate the strength of Millennium as an important partner in the discovery and development of breakthrough personalized medicine products.

Net operating loss for the year ended December 31, 2000 was $75.0 million, $0.39 per share compared to net operating income of $2.4 million or $0.02 per share in 1999. The net operating loss reflects Millennium`s commitment to expand our development capabilities and invest in our growing pipeline.

Expenditures for research and development for the year ended December 31, 2000 were $268.7 million versus $159.9 million in 1999. The increase represents our continued investment in one of the strongest clinical and discovery-stage pipelines in the industry.

General and administrative expenses for the year ended December 31, 2000 were $49.3 million versus $32.9 million for 1999. This increase is due to the expansion of operations and infrastructure necessary to support growth at all levels of Millennium`s business.

As of December 31, 2000, Millennium had approximately $1.5 billion in cash, cash equivalents and marketable securities. During October 2000, the Company raised $767 million in a public offering of its common stock.

"Millennium ended 2000 in its strongest business position ever," said Kevin Starr, chief financial officer of Millennium. "We believe that our substantial cash position of $1.5 billion and a committed revenue source from partners; combined with the strength of our technology platform and a deep early-stage pipeline, with ownership of small molecules, antibodies and predictive medicine programs in our key franchise areas; put us in a unique position to build a company that will truly revolutionize medicine."

Effect of SAB 101

Millennium adopted U.S. Securities and Exchange Commission`s Staff Accounting Bulletin No. 101 (SAB 101) on Revenue Recognition in the fourth quarter of 2000 and recorded a cumulative effect of change in accounting principle related to contract revenues recognized in prior periods. As a result, Millennium recorded a one-time, non-cash charge of $107.7 million. After giving effect to the implementation of SAB 101, Millennium`s 2000 revenue as adjusted was $196.3 million and it had a net operating loss, before acquisition related charges and debt conversion expenses, of $92.0 million or $0.48 per share for the year ended 2000.

Year 2001 Financial Outlook:

This section contains forward-looking guidance about Millennium`s financial outlook in 2001. This guidance excludes the impact of any prior or future potential merger and acquisition initiatives that may occur during the year and includes the impact of SAB 101, as discussed above.




Revenue: Millennium expects to expand its revenue base and demonstrate its leadership capabilities through expanded relationships with existing partners, new technology platforms and major strategic alliances. Revenue guidance for the year 2001 is in the range of $220-240 million.


Net Operating Loss: Millennium expects to continue to make balanced investments in building the company in 2001. The investments include spending on Millennium`s clinical pipeline, its technology platform, and the development capabilities and value creation initiatives necessary to maintain its leadership in the industry. As a result of these investments, our 2001 guidance on loss from operations is in the range of $100-125 million.


Research and Development Expense: As Millennium continues to aggressively advance what we believe is the industry`s leading pipeline, guidance for total research and development spending in the year 2001 is in the range of $375-400 million.


Cash: Guidance for the year is to remain cash neutral by the end of 2001 with a cash balance of approximately $1.5 billion.


Shares outstanding: We anticipate that shares outstanding will increase at approximately the same rate (5-10%) as previous years, excluding equity issued in major alliances and acquisitions.

"We expect to accelerate Millennium`s progress on all fronts even more rapidly in 2001," said Mark Levin, chairman and chief executive officer of Millennium. "We are particularly looking forward to the launch of our first commercial therapeutic product and the first Diagnomic™ test based on our research, major advances in productivity, the downstream development of our pipeline, and the establishment of important new alliances in our core areas."

Year 2000 Company Highlights:


New Alliances

Millennium and Aventis Pharma entered into an alliance valued at up to $450 million with four key components: anti-inflammatory drug development and commercialization, technology development, technology transfer, and an equity investment.



Product Development:

The Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 14 to 1 to recommend accelerated approval of Millennium and ILEX Partners L.P.`s CAMPATH“ investigational humanized monoclonal antibody for patients with chronic lymphocytic leukemia (CLL) who have been treated with alkylating agents and have failed flurarabine therapy.


During the year Millennium presented preclinical and clinical study results on a number of its development programs including an investigational proteasome inhibitor, LDP-341, the first in a new class of anti-cancer agents, and LDP-02, an investigational monoclonal antibody for the potential treatment of inflammatory bowel disease.


Research and Discovery:

Millennium and Bayer AG announced that they have moved more than 70 disease-relevant validated drug targets into high-throughput screening or lead identification in the first two years of the five-year research alliance.


Intellectual Property:

As of December 31, 2000, Millennium owned or is the exclusive licensee under more than 1,400 U.S. and foreign patents and patent applications, including more than 140 issued U.S. patents.


Millennium Predictive Medicine Update:

Millennium acquired the minority equity interest of Millennium Predictive Medicine, Inc. (MPMx), making it a wholly-owned subsidiary of the Company. This move more closely aligned Millennium`s therapeutic and predictive discovery and development efforts, bringing the company closer to its goal of delivering breakthrough products and personalized medicine.


Stock Changes:

Millennium completed a public offering of its common stock that resulted in the Company raising $767 million. Earlier in the year, Millennium raised $400 million by issuing convertible subordinated notes.


Millennium effected two, two-for-one, stock splits of its common shares in the form of stock dividends. These splits occurred on April 18, 2000 and October 4, 2000.


Senior Hires:

Robert Pietrusko, Pharm.D., has joined the company as vice president, worldwide regulatory affairs, reporting to Lee Brettman, M.D., FACP, senior vice president, clinical development and medical affairs. Dr. Pietrusko brings with him an extraordinary depth and breadth of regulatory and development experience from a tenure of 18 years at SmithKline Beecham Pharmaceuticals where he was most recently vice president and director, U.S. regulatory affairs. In his new role at Millennium, Dr. Pietrusko will continue to build the regulatory affairs group, as well as provide seasoned guidance in developing our relationships with regulatory authorities worldwide.


Millennium added the following senior managers to its team in 2000: Paul Hamelin, senior vice president, commercial operations; James Nash, senior vice president, manufacturing; Susan Ward, Ph.D., senior vice president, strategy leadership; Marsha Fanucci, vice president, mergers and acquisitions; Steven Gilman, Ph.D., vice president, inflammation and Michael Spellman, Ph.D, vice president, quality assurance and quality control.

Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Massachusetts, Millennium currently employees more than 1,300 people.

MILLENNIUM PHARMACEUTICALS, INC.
SELECTED CONSOLIDATED FINANCIAL INFORMATION

(in thousands, except per share amounts) Year Ended December 31,
2000 2000
Excluding Including
SAB 101 SAB 101 1999

REVENUES:
Revenue under strategic alliances $213,190 $196,269 $183,679

COSTS AND EXPENSES:
Research and development 268,740 268,740 159,877
General and administrative 49,315 49,315 32,896
Total costs and expenses 318,055 318,055 192,773

OTHER INCOME, NET 29,834 29,834 11,453

NET OPERATING INCOME (LOSS) (BEFORE AMORTIZATION CHARGES, DEBT CONVERSION EXPENSES, ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT, DEEMED PREFERRED STOCK DIVIDEND AND CUMULATIVE EFFECT OF CHANGE IN ACCOUNTING PRINCIPLE) $(75,031) $(91,952) $2,359

Amortization of intangibles (Note 1) (55,123) (55,123) (3,816)
Debt conversion expenses (Note 1) (54,852) (54,852) -
Acquired in-process research and development - - (350,503)
Deemed preferred stock dividend (Note 1) (45,668) (45,668) -
Cumulative effect of change in accounting principle (Note 2) - (107,692) -

Basic net operating income (loss) per share before amortization charges, debt conversion expenses, acquired in-process research and development, deemed preferred stock dividend and cumulative effect of change in accounting principle $(0.39) $(0.48) $0.02

Shares used in computing basic and diluted net income (loss) per share (Note 3,4) 192,835 192,835 145,412


Presentation: The financial information presented above reflects results Excluding and Including the impact of Millennium`s adoption of Staff Accounting Bulletin 101, "Revenue Recognition in Financial Statements" ("SAB 101") respectively, as noted in the column headings.

Note 1: Amortization of intangibles, debt conversion expenses, a one-time deemed preferred stock dividend related to Millennium’s repurchase of Millennium Predictive Medicine, Inc. preferred stock previously held by Becton Dickinson and Company and a one-time non-cash charge for the cumulative effect of change in accounting principle related to Millennium`s adoption of SAB 101 are deducted from Net Operating Income (Loss) to arrive at Net Loss Attributable to Common Stockholders for the year ended December 31, 2000.

Note 2: The cumulative effect of change in accounting principle is a one-time non-cash charge relating to Millennium`s adoption of Staff Accounting Bulletin No. 101, ("SAB 101"). SAB 101 was issued by the Securities and Exchange Commission ("SEC") in December 1999. SAB 101 provides guidance related to revenue recognition policies based on interpretations and practices followed by the SEC. The impact of Millennium`s adoption of SAB 101 was to defer revenue recognition for certain portions of the revenue previously recognized by Millennium under its strategic alliances into future accounting periods.

Note 3: Shares used in computing basic and diluted net income (loss) per share have been restated to give retroactive application to the April 18, 2000 and October 4, 2000 two-for-one stock splits, as applicable.

Note 4: Net Loss Attributable to Common Stockholders, including amortization of intangibles, debt conversion expenses, deemed preferred stock dividend and cumulative effect of change in accounting principle, for the year ended December 31, 2000 (Including SAB 101) was $355,287, or $1.84 per basic and diluted share.




Condensed Consolidated Balance Sheets
(in thousands) December 31, December 31,
2000 1999

Cash, cash equivalents and marketable securities
Other current assets $1,452,367 $261,716
Property and equipment, net 33,213 24,794
Restricted cash and other assets 85,803 59,543
Intangible assets, net 34,599 12,965
Total assets 205,940 182,607
$1,811,922 $541,625
Current liabilities
Capital lease obligations, net $ 225,566 $ 59,163
Long term debt 28,146 27,488
Minority interest 95,927 -
Stockholders’ equity - 15,568
Total liabilities and stockholders’ equity 1,462,283 439,406
$1,811,922 $541,625


MILLENNIUM PHARMACEUTICALS, INC.
SELECTED CONSOLIDATED FINANCIAL INFORMATION


(in thousands, except per share amounts) Three Months Ended December 31,
(unaudited)
2000 2000
Excluding Including
SAB 101 SAB 101 1999

REVENUES:
Revenue under strategic alliances $69,697 $58,686 $55,098

COSTS AND EXPENSES:
Research and development 77,846 77,846 46,601
General and administrative 14,996 14,996 8,989
Total costs and expenses 92,842 92,842 55,590

OTHER INCOME, NET 18,699 18,699 2,217

NET OPERATING INCOME (LOSS) (BEFORE AMORTIZATION CHARGES, DEBT CONVERSION EXPENSES AND ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT) $(4,446) $(15,457) $1,725

Amortization of intangibles (Note 1) (16,512) (16,512) (1,789)
Debt conversion expenses (Note 1) (5,520) (5,520) -
Acquired in-process research and development - - (350,503)

Basic net operating income (loss) per share before amortization charges, debt conversion expenses and acquired in-process research and development $(0.02) $(0.07) $0.01

Shares used in computing basic and diluted net income (loss) per share (Note 2,3) 211,786 211,786 151,532


Presentation: The financial information presented above reflects results Excluding and Including the impact of Millennium`s adoption of Staff Accounting Bulletin 101, "Revenue Recognition in Financial Statements" ("SAB 101") respectively, as noted in the column headings.


Note 1: Amortization of intangibles and debt conversion expenses are deducted from Net Operating Income (Loss) to arrive at Net Loss for the fourth quarter of 2000.

Note 2: Shares used in computing basic and diluted net income (loss) per share have been restated to give retroactive application to the April 18, 2000 and October 4, 2000 two-for-one stock splits, as applicable.


Note 3: Net Loss including amortization of intangibles and debt conversion expenses for the quarter ended December 31, 2000 (Including SAB 101) was $37,489 or $0.18 per basic and diluted shared.



This press release contains "forward-looking statements," including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause Millennium`s actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise


###









--------------------------------------------------------------------------------




--------------------------------------------------------------------------------



--------------------------------------------------------------------------------

Update Notice | Usage Terms | Privacy Policy
© 2000 Millennium Pharmaceuticals, Inc.








Press Releases

Media Info
Virtual Media Kit



Viel Spaß harmon